Neutropenia
📧 Sign up to get email alerts when something new happens for Neutropenia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-14EMA Authorised: Fulphila (pegfilgrastim) — Biosimilar Collaborations Ireland Limited
The EMA authorises Fulphila (pegfilgrastim) as a biosimilar, granting marketing authorization to Biosimilar Collaborations Ireland Limited.
-
EMA approval · 2026-07-14EMA Authorised: Dyrupeg (pegfilgrastim) — CuraTeQ Biologics (Malta) Limited
Dyrupeg (pegfilgrastim) has been authorised by the EMA for neutropenia and cancer indications.
-
EMA approval · 2026-07-14EMA Authorised: Zefylti (filgrastim) — CuraTeQ Biologics (Malta) Limited
Zefylti (filgrastim) has been authorised by EMA for use in neutropenia, hematopoietic stem cell transplantation, and cancer indications.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia [Phase 2]
This clinical trial update covers a Phase 2 prospective evaluation of Xerava (eravacycline) as prophylaxis for infections in patients with h…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections [Phase 3]
Phase 3 clinical trial evaluating mavorixafor in participants with congenital and acquired primary autoimmune and idiopathic chronic neutrop…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Luspatercept for Clonal Cytopenias of Uncertain Significance [Phase 2]
The entry notes an ongoing Phase 2 trial of luspatercept for clonal cytopenias of uncertain significance (CCUS) and related cytopenias such …
-
EMA approval · 2026-03-18EMA Authorised: Cegfila (previously Pegfilgrastim Mundipharma) (pegfilgrastim) — Mundipharma Corporation (Ireland) Limited
The EMA authorised the pegfilgrastim product Cegfila (Mundipharma) for marketing in the European Union.
-
EMA approval · 2026-03-18EMA Authorised: Pelmeg (pegfilgrastim) — Mundipharma Corporation (Ireland) Limited
EMA authorised Pelmeg, a pegfilgrastim biosimilar by Mundipharma, to reduce the duration of neutropenia and the risk of febrile neutropenia …
-
EMA approval · 2026-03-02EMA Authorised: Nivestim (filgrastim) — Pfizer Europe MA EEIG
EMA has authorized Nivestim (filgrastim) from Pfizer Europe MA EEIG as a biosimilar to treat neutropenia in cancer patients and in the conte…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection
A real-world study is evaluating Mecapegfilgrastim injections to prevent neutropenia in patients undergoing tumor treatment; the trial is cu…
-
EMA approval · 2026-02-24EMA Authorised: Vivlipeg (pegfilgrastim) — Biosimilar Collaborations Ireland Limited
The EMA authorised Vivlipeg, a biosimilar pegfilgrastim. The product is indicated for neutropenia and related febrile neutropenia in cancer …
-
EMA approval · 2026-02-19EMA Authorised: Fulphila (pegfilgrastim) — Biosimilar Collaborations Ireland Limited
EMA authorised Fulphila, a pegfilgrastim biosimilar by Biosimilar Collaborations Ireland Limited. The approval covers its use to reduce the …
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers [NA]
A clinical trial comparing diosmin-hesperidin to loratadine for preventing G-CSF–induced bone pain in patients with hematologic malignancies…
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases [Phase 1, Phase 2]
This clinical trial update describes an early-phase study evaluating sequential cadaveric lung transplantation followed by bone marrow trans…
-
CLINICAL_TRIALS trial_result · 2025-12-11Clinical Trial Update: DIStinguishing ChildrEn at Low Risk of Severe infectioN in Case of Febrile Neutropenia-7: Impact Study of a Clinical Decision Rule [NA]
Trial update noting the termination status of the DIStinguishing Children at Low Risk of Severe infection in Case of Febrile Neutropenia-7 t…
-
EMA approval · 2025-12-08EMA Authorised: Neulasta (pegfilgrastim) — Amgen Europe B.V.
EMA authorised Neulasta (pegfilgrastim) by Amgen Europe B.V. to reduce the risk of neutropenia, febrile neutropenia, and chemotherapy-induce…
-
FDA approval · 2025-11-28FDA Approved: ARMLUPEG — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved ARMLUPEG (pegfilgrastim-unne) from Lupin Pharmaceuticals in an Original Biologics License Application. Pegfilgrastim-unne is a …
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: PC001- A Study to Evaluate the Usability of PointCheck [NA]
The PC001 usability study for PointCheck conducted by Leuko Labs has completed.
-
EMA approval · 2025-09-29EMA Authorised: Zefylti (filgrastim) — CuraTeQ Biologics s.r.o
The European Medicines Agency authorised Zefylti (filgrastim) as a biosimilar for neutropenia, hematopoietic stem cell transplantation, and …
-
CLINICAL_TRIALS trial_result · 2025-09-08Clinical Trial Update: Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis [NA]
A completed clinical trial evaluating hepatosplenic candidiasis using PET scans and immune response analysis in patients with invasive candi…
-
FDA approval · 2025-08-21FDA Approved: ZARXIO — Supplemental Application (Sandoz Inc.)
The FDA approved a supplemental application for Zarxio (filgrastim-sndz) submitted by Sandoz Inc. The action concerns updates under a supple…
-
FDA label_change · 2025-08-18FDA Approved: NEULASTA — Supplemental Application (Amgen, Inc)
FDA-approved a supplemental application for NEULASTA (pegfilgrastim) submitted by Amgen.
-
EMA approval · 2025-08-12EMA Authorised: Dyrupeg (pegfilgrastim) — CuraTeQ Biologics s.r.o
EMA authorises Dyrupeg (pegfilgrastim) by CuraTeQ Biologics for use in neutropenia and cancer indications.
-
CLINICAL_TRIALS research · 2025-07-15Clinical Trial Update: Serial Blood Count Study [EARLY_Phase 1]
An early-phase 1 serial blood count study investigating neutropenia is currently recruiting at the University of Washington. The trial focus…
-
EMA approval · 2025-07-08EMA Authorised: Filgrastim Hexal (filgrastim) — Hexal AG
EMA authorised Filgrastim Hexal (filgrastim), a biosimilar granulocyte colony-stimulating factor, for neutropenia management in cancer patie…